November 14, 2006 -- Abbott received approval of an add-on indication for arthritis medication Humira; Human Genome Sciences said LymphoStat-B helped lupus patients in a 24-week follow-up to a year-long trial; the FDA gave Priority Review to Soliris, a treatment for Paroxysmal Nocturnal Homoglobinuria from Alexion; Bristol-Myers Squibb released data showing Orencia was effective in children with juvenile idiopathic arthritis; EntreMed announced positive pre-clinical results for 2-methoxyestradiol (2ME2) against rheumatoid arthritis; Acambis PLC said its smallpox vaccination is out of the running for the US biodefense stockpile; Dyax presented positive data from trials of DX-88 for hereditary angioedema, and CuraGen and TopoTarget began a Phase II test of a drug for ovarian cancer. The Centient Biotech 200™ closed with a 9 point gain at 3955, a rise of .23%. More details...
